Menu

Cohance Lifesciences: Can a recovery justify its valuation?
🖼️

Cohance Lifesciences: Can a recovery justify its valuation?

The Indian Express·Rahul Rao·13 days ago
#2eZ6v03z
Reading 0:00
15s threshold

News

Smart Stocks

Cohance Lifesciences: Can a recovery justify its valuation?

Cohance Lifesciences business numbers have been hard to stomach. FY26 revenue fell 13% and adjusted EBITDA nearly halved. Q1 FY27 revenue fell 23%, adjusted EBITDA margin dropped to 2.2%, and the company reported a net loss of Rs 45 crore. At around Rs 479 per share, Cohance’s market capitalisation is approximately Rs 17,000 crore, and […]

The easiest way to understand Cohance is to start with how it was put together. (File photo)

12 min read Nov 4, 2026 07:30 AM IST First published on: Nov 4, 2026 at 07:30 AM IST

Cohance Lifesciences business numbers have been hard to stomach.

FY26 revenue fell 13% and adjusted EBITDA nearly halved. Q1 FY27 revenue fell 23%, adjusted EBITDA margin dropped to 2.2%, and the company reported a net loss of Rs 45 crore.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.